IL4 and Alzheimer disease: Another highly relevant topical therapy for the treatment of AD is the use of calcineurin inhibitors (TCIs), which are cytoplasmic proteins strongly associated with the inflammatory response of lymphocytes and dendritic cells in the skin; these proteins act mainly as transcription factors for IL-2, IL-3, IL-4 and TNF-α (Beltran and Castro 2006).The topical TCIs available and recommended by the JTF guide are pimecrolimus and tacrolimus, whose therapeutic responses are similar to those of class 5 and 6/7 TCSs, respectively (Chu et al. 2024).